BD Announces New Software Release For Pyxis Enterprise Solution

BD announced general availability of the latest software release of Pyxis™ ES System, delivering patient safety and workflow benefits for health systems’ medication management.

Key innovations and enhancements in the new software version include:

  • Advanced server scalability and optimization to meet the needs of growing health systems with flexible deployment options and centralized database management features.
  • Expanded return and waste processes to support patient safety and clinical efficiency with workflow, documentation and interface enhancements.
  • Support for advanced half-height CUBIE™ drawers and pockets, bringing enhanced security and reliability to the flexible storage space and configurability options for which CUBIE technology is known.
  • New Medication Label Module that can print a patient-specific medication label upon removal to support patient safety and compliance with Joint Commission requirements. Proper medication labeling can help reduce medication errors, missing doses, and waste caused by mislabeled, open multi-use medications.
  • Enhanced server functionality to provide more flexibility through medication configuration and user permissions, plus improved reporting features. These features support system and data security as well as medication safety and standardization.

The Pyxis ES platform promotes a patient-centric healthcare model, leveraging healthcare information technology systems and Active Directory integration to enable a single health system formulary, simplified identity management and workflow enhancements. The platform enables pharmacists to manage medications remotely and eliminate redundant tasks.  Nurses can readily access secured medications using safe, simple workflows centered on the patient.

A press release can be found here.

Revascularization better for peripheral arterial disease

Patients with intermittent claudication, a form of peripheral arterial disease, who had circulation-restoring procedures called revascularization had better quality of life and fewer symptoms a year later than patients who underwent medical management in a recent study.

Emily Beth Devine, UW associate professor of pharmacy,  and her colleagues, compared the effectiveness of two treatments for intermittent claudication: a medical management program consisting of walking exercise, medicines, and smoking cessation counseling; and revascularization by surgically unblocking clogged blood vessels or by implanting tiny wire mesh tubes called stents into the vessels to help keep arteries open.

The study was conducted at 15 clinics associated with 11 hospitals in Washington state. Participants were 21 years or older with newly diagnosed or established intermittent claudication. A total of 323 adults were enrolled, with 282 (87 percent) receiving the medical treatment program. At the start of the study, the average duration of disease was longer for participants who received the medical intervention program, while those who underwent revascularization reported more severe disease.

Full story can be found from University of Washington website.